Biopharma Middle East and Africa (Biopharma-mea) today announced that it has entered into an exclusive agreement with LEO Pharma to commercialize the Thrombosis Portfolio in Saudi Arabia.

 

Biopharma views this collaboration with LEO Pharma as a significant stride towards enhancing patient care in Saudi Arabia. By continuing to commercialize the Thrombosis Portfolio into the Saudi market, we aim to address the need for treatment options in the field of thrombosis. This partnership aligns with our commitment to bringing healthcare solutions to the region, ensuring that patients have access to more treatment options. We believe that by making the Thrombosis Portfolio available, we are not only offering a therapeutic option but also contributing to overall healthcare in Saudi Arabia.